Amaç: Bu çalışma kemik sarkomu için maksimum standart alım değerinin (SUV max ) 18 F-floro-deoksiglukoz pozitron emisyon tomografisi/bilgisayarlı tomografi ( 18 FDG-PET/BT) üzerindeki prognostik anlamı değerlendirildi. Hastalar ve yöntemler: Eylül 2013 -Eylül 2017 tarihleri arasında ilk evreleme için 18 FDG-PET/BT uygulanan, patolojik olarak kanıtlanmış kemik sarkomu olan 34 hasta (24 erkek, 10 kadın; ort. yaş 36.6±24.2 yıl; dağılım, 5-77 yıl) geriye dönük olarak değerlendirildi. Primer lezyonların SUV maks 'ı ölçüldü.
Bone sarcomas are rare malignant mesenchymal derived bone tumors, which may or may not produce osteoid. Despite their rarity, primary malignant bone tumors comprise approximately 5% of all childhood and approximately 1% of all adult cancers in European countries. [1, 2] Primary malignant bone tumors include two major sarcomas of children and young adults: osteosarcoma and Ewing sarcoma. [3] [4] [5] The diagnostic work-up of bone sarcoma includes conventional imaging modalities that mainly provide morphologic information on the primary tumor and potential metastases. Functional imaging offers functional data on tumor metabolism. [6] 18 F-fluoro-2-deoxyglucose positron emission tomography/computed tomography ( 18 FDG-PET/CT) is a dual-modality imaging technique that combines metabolic (PET) and anatomic (CT) evaluation of the malignancy. FDG accumulation is thought to be indicative of the metabolic activity of a targeted lesion, increased in proportion to their higher proliferative index, undifferentiating grade and metastatic spread. [7] Standardized uptake value (SUV), a commonly used semi-quantitative measure of FDG uptake, represents the point of greatest metabolic activity in the tumor, and its physical location can be ascertained with standard imaging software. High metabolic activity on FDG-PET has been shown to correlate with overall survival and thus provide additional information that may guide management. Therefore, in this study, we aimed to evaluate the prognostic significance of maximum SUV (SUV max ) on 18 FDG-PET/CT for bone sarcoma. [8] FDG-PET/CT before treatment, and if they had insufficient clinical data with no histopathology of the primary tumor or clinical and/or radiologic follow-up of a minimum of six months.
PATIENTS AND METHODS
Whole body PET/CT imaging was performed on a biograph (Siemens Biograph 6, Chicago, IL, USA) using a full-ring HI-REZ LSO PET and a six-slice CT scanner. The 18 FDG-PET/CT scans were acquired after patients had fasted for at least six hours and had blood glucose levels lower than 200 mg/dL. The lowdose CT image acquisition was performed with oral contrast material, followed by PET image acquisition.
18 F-fluoro-2-deoxyglucose PET/CT images were analyzed in at least three planes transaxial, coronal and sagittal in the gray scale color table for PET. In patients with metallic implants or prosthesis in situ, images without attenuation correction were also evaluated to rule out overcorrection artifacts. To perform a quantitative analysis, the SUV was calculated using the following equation: decay-corrected activity [MBq]/mL of tissue volume/injected F-18 FDG activity [MBq]/g of body weight. [8] The SUV max of each primary and/or most intense metastatic lesion was measured. Cumulative survival rate was calculated to evaluate the prognostic value of the 18 FDG-PET/CT findings. Survival time was defined as the time from pretreatment 18 FDG-PET/CT scan to the date of the detection of death or to the date of the last patient file at our hospital.
Statistical analysis
Statistical analyses were performed using the IBM SPSS version 22.0 software (IBM Corp., Armonk, NY, USA). The normal distribution of parameters was evaluated by the Shapiro-Wilk test. Student t-test was used to compare descriptive statistical methods (mean, standard deviation, frequency) as well as the two-group comparison of parameters with normal distribution in the comparison of the quantitative data. Chi-square test, Fisher-FreemanHalton test, Fisher's exact test and continuity (Yates) correction were used for comparison of qualitative data. Pearson's correlation analysis was used when the relationships between the parameters with normal distribution suitability were examined.
Receiver operating characteristic (ROC) analysis was used for cut-off point detection. Overall cumulative survival was analyzed by the Kaplan-Meier method and differences in survival between subgroups were compared using a log-rank test. Significance was assessed at p<0.05 level.
RESULTS
Patients' characteristics are listed in Table I . Thirty two percent of the patients were 19 years of age or under, while 68% were over 19 years. Tumor diameter values ranged from 3 to 18 cm with a mean of 6.97±5.1. SUV max ranged from 3 to 45 with a mean of 12.46±8.12.
Of the patients, 61.8% had pathological type of osteosarcoma, 32.4% had Ewing sarcoma, and 5.8% had chondrosarcoma. Tumor sites were located in the lower extremity in 24 patients (72.9%), in the upper extremity in five patients (14.5%), in the vertebrae in three patients (8.8%), in the trunk in one patient (3%) and in the cranium in one patient (3%). Of the 34 patients, 41.1% were progressive, 32.4% were in remission, 8.8% were in partial regression, 14.7% were local recurrence and 3% were stable.
Follow-up times ranged from 6 to 73 months with a mean of 33±21.
Distant metastases were present in 14 cases (41.1%), lungs being the most common (Figure 1) . Mean tumor diameter of the progressive group was statistically significantly higher than the nonprogressive group (p<0.05). The mean SUV max of the progressive group was statistically significantly higher than the non-progressive group (p<0.05). There was no statistically significant relationship between progression and age and gender (p>0.05).
In progressive patients, the rate of tumor placement at lower extremity (70.7%) was statistically significantly higher than the non-progressive group (p<0.05). The rate of distant metastases (82.1%) in the progressive group was statistically significantly higher than the non-progressive group (p<0.05).
In cases with bone sarcoma, ROC curve was drawn for SUV max in case of progression ( Figure 2 ). The area under the curve was 0.782 and the standard error was 0.09. The area under the ROC curve was significantly higher than 0.5 (p<0.05). The cut-off point for SUV max in the definition of progression was 8. Sensitivity of this value was 90%, specificity was 71.4%, positive predictive value was 81.8% and negative predictive value was 82.4%.
Of the 34 patients included in the survival analysis, mortality rate was 14.7% (n=5). Mean survival time was 62.1±4.4 months and median duration was 72 months (Figure 3) . The cumulative survival rates of one year, three years, and five years were 87±0.05%, 74±0.08%, and 67±0.09%, respectively. The cumulative survival rate was 79.1±0.08%. 
DISCUSSION
The importance of 18 FDG-PET/CT in cancer management has been established due to its great value in detection, tumor staging and grading, local or distant recurrence detection and follow-up management. [9] The easily-readable SUV max , which reflects the highest metabolic activity, is currently the most applied parameter in clinical practice. Eary et al. [10] were the first to suggest that SUV max is a statistically significant independent predictor of sarcoma patient survival and tumors with higher SUV max had significantly poorer prognosis.
Recent studies supported that baseline SUV max using 18 FDG-PET/CT demonstrates independent properties beyond histologic grading for prediction of survival. Andersen et al. [11] reported a cut-off point of 9, whereas Hwang et al. [7] and Skamene et al. [12] revealed cut-off points of 5.8 and 10.3, respectively. In our study, findings were consistent with the literature stating that higher SUV max has significantly poor survival outcomes in sarcoma patients. High SUV max was associated with worse bone sarcoma, using a cut off-point of 8, a strong correlation was found between SUV and bone sarcoma.
In the literature, the five-year overall survival rate for bone sarcoma is 63.6%. [13] In our study, we concluded that five-year survival rate for bone sarcoma is 79±0.08%.
This retrospective study has several limitations that warrant consideration. [8] A major limitation was the relatively small number of patients included. Secondly, the patient group was heterogeneous, containing both adult and pediatric patients. Thirdly, the study was inherently limited by its retrospective design. And finally, we only analyzed patients in a single institution.
In conclusion, semi-quantitative estimation of primary tumor metabolic activity in terms of baseline SUV max using 18 FDG-PET/CT can predict the overall survival of patients with bone sarcoma. The predictive efficacy of SUV max in diverse clinical settings should be validated in future studies.
